Generic Name: ramucirumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Eli Lilly

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

General Info

Cyramza is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2, which is important for the development of blood vessels that feed tumors.

The RAINBOW and REGARD trials showed that Cyramza slows disease progression and improves survival in people with stomach or gastroesophageal junction cancer. The RAISE and REVEL trials showed it improves progression-free and overall survival in people with metastatic colorectal cancer and those with nonsquamous or squamous metastatic non-small-cell lung cancer. The REACH-2 trial showed Cyramza improves progression-free and overall survival in previously treated liver cancer patients with high alpha fetoprotein levels. The RELAY trial showed that Cyramza plus Tarceva (erlotinib) delayed disease progression in people with non-small-cell lung cancer with certain EGFR mutations. Cyramza was first approved in 2014.


Dosing Info:

Cyramza is given by intravenous infusion. It may be used alone or with chemotherapy.

Side Effects

Common side effects include high blood pressure and diarrhea. Potential serious side effects may include blood clots in arteries, severe hypertension, stomach or intestinal perforation and infusion reactions. The Cyramza label includes a warning about the risk of severe bleeding (hemorrhage).

For More Info:

Patient Assistance Program Info:

Last Reviewed: June 1, 2020